Commonwealth Equity Services
XERS icon

Commonwealth Equity Services’s Xeris Biopharma Holdings XERS Stock Holding History

Commonwealth Equity Services’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
203,116
+5,301
+3% +$35.1K ﹤0.01% 2472
2025
Q4 		$1.55M Buy
197,815
+72
+0% +$567 ﹤0.01% 2191
2025
Q3 		$1.61M Hold
197,743
– – ﹤0.01% 2192
2025
Q2 		$923K Buy
197,743
+300
+0.2% +$1.38K ﹤0.01% 2640
2025
Q1 		$1.08M Buy
197,443
+10,000
+5% +$40.4K ﹤0.01% 2389
2024
Q4 		$635K Hold
187,443
– – ﹤0.01% 2771
2024
Q3 		$534K Buy
187,443
+440
+0.2% +$1.13K ﹤0.01% 2847
2024
Q2 		$421K Hold
187,003
– – ﹤0.01% 2987
2024
Q1 		$413K Hold
187,003
– – ﹤0.01% 2990
2023
Q4 		$439K Buy
187,003
+40,769
+28% +$75.2K ﹤0.01% 2834
2023
Q3 		$272K Hold
146,234
– – ﹤0.01% 3118
2023
Q2 		$383K Hold
146,234
– – ﹤0.01% 2839
2023
Q1 		$238 Sell
146,234
-1,000
-0.7% -$1.25K ﹤0.01% 3167
2022
Q4 		$195K Hold
147,234
– – ﹤0.01% 3243
2022
Q3 		$229K Hold
147,234
– – ﹤0.01% 3058
2022
Q2 		$226K Hold
147,234
– – ﹤0.01% 3093
2022
Q1 		$376K Sell
147,234
-50,000
-25% -$122K ﹤0.01% 2772
2021
Q4 		$577K Buy
197,234
+99,650
+102% +$215K ﹤0.01% 2407
2021
Q3 		$239K Sell
97,584
-3,000
-3% -$8.71K ﹤0.01% 3123
2021
Q2 		$409K Buy
100,584
+3,350
+3% +$12.8K ﹤0.01% 2630
2021
Q1 		$438K Buy
97,234
+2,000
+2% +$10.8K ﹤0.01% 2434
2020
Q4 		$468K Buy
95,234
+1,000
+1% +$5K ﹤0.01% 2195
2020
Q3 		$558K Buy
94,234
+2,300
+3% +$9.2K ﹤0.01% 1886
2020
Q2 		$244K Buy
91,934
+81,934
+819% +$285K ﹤0.01% 2435
2020
Q1 		$19K Buy
+10,000
New +$43K ﹤0.01% 2760

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commonwealth Equity Services's XERS Position: Q1 2026 in Review

Commonwealth Equity Services increased its Xeris Biopharma Holdings (XERS) stake by 2.7% in Q1 2026, buying an estimated $35.1K and bringing the position to 203,116 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2472.

Commonwealth Equity Services first reported a position in XERS in Q1 2020 and has held it in 25 quarters since. The position peaked at $1.61M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Commonwealth Equity Services held 203,116 shares of Xeris Biopharma Holdings worth $1.18M as of Q1 2026.
  • Commonwealth Equity Services bought 5,301 Xeris Biopharma Holdings shares in Q1 2026, an estimated $35.1K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #2472 holding.
  • Commonwealth Equity Services first reported a position in Xeris Biopharma Holdings in Q1 2020 and has held it in 25 quarters since.
  • Commonwealth Equity Services's Xeris Biopharma Holdings position peaked at $1.61M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.